We have been following two lines of research for developing strategies to utilize NO in cancer treatment. The first is by the use of NO donor compounds while the second is to control its production from the enzyme nitric oxide synthase whose activity is modulated by different cytokines. We have catalogued the effect of various NO donors on sensitizing hypoxic mammalian cells to radiation as well as evaluating the effects of these compounds on the cytotoxicity of different alkylating agents. We discovered that there is a significant difference between NO donors with respect to these modalities of cancer treatment. Chemical donors such as NONOates and nitrosothiols sensitize cells to radiation under hypoxia, however, only NO derived from NONOates sensitize chemotherapeutic drugs such as cisplatin, melphalan, and thiotepa. We have shown that NO from NONOates can inhibit DNA repair proteins such as ligase and this appears to be the mechanism by which cells are sensitized to chemotherapeutic agents. Cytokine stimulation of some cells results in not only NO formation, but also other reactive chemical species such as superoxide (O2-) as well. We have explored the chemistry between NO and O2- which depends on the relative rates of formation of these radicals. Depending on the relative production of either radical, nitrosative and oxidative stress can be modified. We have preliminary results which suggest that the cytotoxicity of different chemotherapeutic agents may depend on either an oxidative or nitrosative pathway. It has been shown that immune cells as well as some cancer cells can be stimulated by cytokines to generate NO as well as other oxidants. We have discovered that NO formation from cytokine stimulated immune cells can be enhanced by radiation adding an important tool to modulating endogenously formed NO. We have begun to explore the effects of cytokine stimulated NO on the cytotoxicity of different antineoplastic agents and radiation. Taken together, we will be able to show NO and other oxidants can be modulated by different components of the immune system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007281-03
Application #
2464487
Study Section
Special Emphasis Panel (RBB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Switzer, Christopher H; Flores-Santana, Wilmarie; Mancardi, Daniele et al. (2009) The emergence of nitroxyl (HNO) as a pharmacological agent. Biochim Biophys Acta 1787:835-40
Ridnour, Lisa A; Thomas, Douglas D; Switzer, Christopher et al. (2008) Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 19:73-6
Donzelli, Sonia; Espey, Michael Graham; Flores-Santana, Wilmarie et al. (2008) Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine. Free Radic Biol Med 45:578-84
Matsumoto, Shingo; Espey, Michael Graham; Utsumi, Hideo et al. (2008) Dynamic monitoring of localized tumor oxygenation changes using RF pulsed electron paramagnetic resonance in conscious mice. Magn Reson Med 59:619-25
Wink, David A; Paolocci, Nazareno (2008) Mother was right: eat your vegetables and do not spit! When oral nitrate helps with high blood pressure. Hypertension 51:617-9
Tocchetti, Carlo G; Wang, Wang; Froehlich, Jeffrey P et al. (2007) Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res 100:96-104
Isenberg, Jeff S; Jia, Yifeng; Fukuyama, Julia et al. (2007) Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282:15404-15
Prueitt, Robyn L; Boersma, Brenda J; Howe, Tiffany M et al. (2007) Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 120:796-805
Paolocci, Nazareno; Jackson, Matthew I; Lopez, Brenda E et al. (2007) The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther 113:442-58
Isenberg, Jeff S; Hyodo, Fuminori; Matsumoto, Ken-Ichiro et al. (2007) Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109:1945-52

Showing the most recent 10 out of 34 publications